195 related articles for article (PubMed ID: 24239623)
21. Structure-activity relationships of benzimidazole-based selective inhibitors of the mitogen activated kinase-5 signaling pathway.
Flaherty PT; Chopra I; Jain P; Monlish D; Cavanaugh J
Bioorg Med Chem; 2010 Nov; 18(22):8054-60. PubMed ID: 20965737
[TBL] [Abstract][Full Text] [Related]
22. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.
Garofalo AW; Adler M; Aubele DL; Brigham EF; Chian D; Franzini M; Goldbach E; Kwong GT; Motter R; Probst GD; Quinn KP; Ruslim L; Sham HL; Tam D; Tanaka P; Truong AP; Ye XM; Ren Z
Bioorg Med Chem Lett; 2013 Apr; 23(7):1974-7. PubMed ID: 23453068
[TBL] [Abstract][Full Text] [Related]
23. Fluid shear stress inhibits TNF-mediated JNK activation via MEK5-BMK1 in endothelial cells.
Li L; Tatake RJ; Natarajan K; Taba Y; Garin G; Tai C; Leung E; Surapisitchat J; Yoshizumi M; Yan C; Abe J; Berk BC
Biochem Biophys Res Commun; 2008 May; 370(1):159-63. PubMed ID: 18358237
[TBL] [Abstract][Full Text] [Related]
24. ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation.
Pearson G; English JM; White MA; Cobb MH
J Biol Chem; 2001 Mar; 276(11):7927-31. PubMed ID: 11118448
[TBL] [Abstract][Full Text] [Related]
25. ERK5: structure, regulation and function.
Nithianandarajah-Jones GN; Wilm B; Goldring CE; Müller J; Cross MJ
Cell Signal; 2012 Nov; 24(11):2187-96. PubMed ID: 22800864
[TBL] [Abstract][Full Text] [Related]
26. Design and Synthesis of Pyrrolo[2,3-
Williamson DS; Smith GP; Mikkelsen GK; Jensen T; Acheson-Dossang P; Badolo L; Bedford ST; Chell V; Chen IJ; Dokurno P; Hentzer M; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Wang Y; Christensen KV
J Med Chem; 2021 Jul; 64(14):10312-10332. PubMed ID: 34184879
[TBL] [Abstract][Full Text] [Related]
27. The MAP kinase ERK5 binds to and phosphorylates p90 RSK.
Ranganathan A; Pearson GW; Chrestensen CA; Sturgill TW; Cobb MH
Arch Biochem Biophys; 2006 May; 449(1-2):8-16. PubMed ID: 16626623
[TBL] [Abstract][Full Text] [Related]
28. GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.
Reith AD; Bamborough P; Jandu K; Andreotti D; Mensah L; Dossang P; Choi HG; Deng X; Zhang J; Alessi DR; Gray NS
Bioorg Med Chem Lett; 2012 Sep; 22(17):5625-9. PubMed ID: 22863203
[TBL] [Abstract][Full Text] [Related]
29. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
Henderson JL; Kormos BL; Hayward MM; Coffman KJ; Jasti J; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD; Galatsis P
J Med Chem; 2015 Jan; 58(1):419-32. PubMed ID: 25353650
[TBL] [Abstract][Full Text] [Related]
30. Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.
Nguyen D; Lemos C; Wortmann L; Eis K; Holton SJ; Boemer U; Moosmayer D; Eberspaecher U; Weiske J; Lechner C; Prechtl S; Suelzle D; Siegel F; Prinz F; Lesche R; Nicke B; Nowak-Reppel K; Himmel H; Mumberg D; von Nussbaum F; Nising CF; Bauser M; Haegebarth A
J Med Chem; 2019 Jan; 62(2):928-940. PubMed ID: 30563338
[TBL] [Abstract][Full Text] [Related]
31. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.
Miduturu CV; Deng X; Kwiatkowski N; Yang W; Brault L; Filippakopoulos P; Chung E; Yang Q; Schwaller J; Knapp S; King RW; Lee JD; Herrgard S; Zarrinkar P; Gray NS
Chem Biol; 2011 Jul; 18(7):868-79. PubMed ID: 21802008
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of novel 6,11-dihydro-5H-benzo[e]pyrimido- [5,4-b][1,4]diazepine derivatives as potential c-Met inhibitors.
Huang D; Huang L; Zhang Q; Li J
Eur J Med Chem; 2017 Nov; 140():212-228. PubMed ID: 28938137
[TBL] [Abstract][Full Text] [Related]
33. Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma.
Gavine PR; Wang M; Yu D; Hu E; Huang C; Xia J; Su X; Fan J; Zhang T; Ye Q; Zheng L; Zhu G; Qian Z; Luo Q; Hou YY; Ji Q
BMC Cancer; 2015 Jun; 15():454. PubMed ID: 26040563
[TBL] [Abstract][Full Text] [Related]
34. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
[TBL] [Abstract][Full Text] [Related]
35. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C.
Kato Y; Kravchenko VV; Tapping RI; Han J; Ulevitch RJ; Lee JD
EMBO J; 1997 Dec; 16(23):7054-66. PubMed ID: 9384584
[TBL] [Abstract][Full Text] [Related]
36. Identification of pharmacological inhibitors of the MEK5/ERK5 pathway.
Tatake RJ; O'Neill MM; Kennedy CA; Wayne AL; Jakes S; Wu D; Kugler SZ; Kashem MA; Kaplita P; Snow RJ
Biochem Biophys Res Commun; 2008 Dec; 377(1):120-5. PubMed ID: 18834865
[TBL] [Abstract][Full Text] [Related]
37. The tale of proteolysis targeting chimeras (PROTACs) for Leucine-Rich Repeat Kinase 2 (LRRK2).
Konstantinidou M; Oun A; Pathak P; Zhang B; Wang Z; Ter Brake F; Dolga AM; Kortholt A; Dömling A
ChemMedChem; 2021 Mar; 16(6):959-965. PubMed ID: 33278061
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1.
Wei L; Gao X; Warne R; Hao X; Bussiere D; Gu XJ; Uno T; Liu Y
Bioorg Med Chem Lett; 2010 Jul; 20(13):3897-902. PubMed ID: 20627557
[TBL] [Abstract][Full Text] [Related]
39. 14-3-3beta binds to big mitogen-activated protein kinase 1 (BMK1/ERK5) and regulates BMK1 function.
Zheng Q; Yin G; Yan C; Cavet M; Berk BC
J Biol Chem; 2004 Mar; 279(10):8787-91. PubMed ID: 14679215
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
